Ser734
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser734  -  DAPK1 (human)

Site Information
NsSRFPPsPLASKPT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454887
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 , 4 , 5 ) , mutation of modification site ( 1 , 6 ) , phospho-antibody ( 1 , 6 ) , western blotting ( 1 , 6 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell large cell lung carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 1 ) , ERK2 (human) ( 6 )
Kinases, in vitro:
ERK2 (human) ( 6 )
Treatments:
PD98059 ( 6 ) , serum ( 6 )

Downstream Regulation
Effects of modification on DAPK1:
enzymatic activity, induced ( 6 )
Effects of modification on biological processes:
apoptosis, altered ( 6 ) , apoptosis, induced ( 1 ) , cell adhesion, inhibited ( 1 )

References 

1

Kwon T, et al. (2016) DANGER is involved in high glucose-induced radioresistance through inhibiting DAPK-mediated anoikis in non-small cell lung cancer. Oncotarget 7, 7193-206
26769850   Curated Info

2

Moritz A (2006) CST Curation Set: 1784; Year: 2006; Biosample/Treatment: cell line, HEL/Flt3 inhibitor; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

3

Moritz A (2006) CST Curation Set: 1786; Year: 2006; Biosample/Treatment: cell line, HEL/-; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

4

Farnsworth C (2005) CST Curation Set: 803; Year: 2005; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

5

Farnsworth C (2005) CST Curation Set: 773; Year: 2005; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

6

Chen CH, et al. (2005) Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J 24, 294-304
15616583   Curated Info